Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Sort descending Date Submission Received Date Recommendation Issued
Tafinlar Dabrafenib Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Rydapt Midostaurin Systemic Mastocytosis Do not reimburse Complete
Vocabria and Cabenuva cabotegravir sodium cabotegravir-rilpivirine HIV-1 infection Reimburse with clinical criteria and/or conditions Complete
Kisqali Ribociclib HR+, HER2- advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Complete
Kisqali Ribociclib with Fulvestrant +Fulvestrant for HR+, HER2- advanced or metastatic breast cancer Reimburse with clinical criteria and/or conditions Complete
Nubeqa Darolutamide non-metastatic castration resistant prostate cancer (nmCRPC) Reimburse with clinical criteria and/or conditions Complete
Taltz ixekizumab Ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Lonsurf Trifluridine-Tipiracil Gastric Cancer Reimburse with clinical criteria and/or conditions Complete
Cablivi caplacizumab Acquired thrombotic thrombocytopenic purpura (aTTP) Do not reimburse Complete
Mayzent siponimod Secondary progressive multiple sclerosis Reimburse with clinical criteria and/or conditions Complete